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Simple Summary: Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90%
of all pancreatic cancers, is an extremely aggressive and lethal disease. It is considered a silent killer
due to a largely asymptomatic course and late clinical presentation. Earlier detection of the disease
would likely have a great impact on changing the currently poor survival figures for this malignancy.
In this comprehensive review, we assessed over 4000 reports on non-invasive PDAC biomarkers
in the last decade. Applying the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
tool, we selected and reviewed in more detail 49 relevant studies reporting on the most promising
candidate biomarkers. In addition, we also highlight the present challenges and complexities of
translating novel biomarkers into clinical use.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part
to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently
the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to
detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with
improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and
more effective therapeutic interventions, changing thus the present dismal survival figures. The
aim of this study was to systematically and comprehensively review the scientific literature on non-
invasive biomarkers in biofluids such as blood, urine and saliva that were attempting earlier PDAC
detection. The search performed covered a period of 10 years (January 2010—August 2020). Data
were extracted using keywords search in the three databases: MEDLINE, Web of Science and Embase.
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was applied for study
selection based on establishing the risk of bias and applicability concerns in Patient Selection, Index
test (biomarker assay) and Reference Standard (standard-of-care diagnostic test). Out of initially over
4000 published reports, 49 relevant studies were selected and reviewed in more detail. In addition, we
discuss the present challenges and complexities in the path of translating the discovered biomarkers
into the clinical setting. Our systematic review highlighted several promising biomarkers that could,
either alone or in combination with CA19-9, potentially improve earlier detection of PDAC. Overall,
reviewed biomarker studies should aim to improve methodological and reporting quality, and novel
candidate biomarkers should be investigated further in order to demonstrate their clinical usefulness.
However, challenges and complexities in the path of translating the discovered biomarkers from
the research laboratory to the clinical setting remain and would have to be addressed before a more
realistic breakthrough in earlier detection of PDAC is achieved.
Keywords: pancreatic ductal adenocarcinoma; systematic review; biomarkers; QUADAS-2; early
detection; non-invasive
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90%
of all pancreatic cancers, is an extremely aggressive disease and one of the most lethal
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cancers. Its incidence almost equals its mortality, and it has a 5-year survival of only around
9% [1,2]. It caused 7800 deaths in the United Kingdom (UK) in 2018 alone, and, according
to GLOBOCAN, there were 458,918 new cases of pancreatic cancer and 432,242 pancreatic
cancer-related deaths worldwide in the same year [3]. Furthermore, PDAC incidence is
steadily increasing [4–7].
PDAC is considered a silent killer due to a largely asymptomatic course, late clinical
presentation, and rapid progression [8], with fewer than 20% of PDAC patients being
diagnosed at early, resectable stages I and II [9,10]. Importantly, if PDAC is detected when
still a localized disease, the 5-year survival is around 32% [11], but it can approach 70%
following resection of incidentally diagnosed stage I tumors [12–14]. It is estimated that it
takes at least 10 years between initiating mutation and the birth of parental founder [15];
combined with an increased PDAC incidence with age [5], resectable PDAC has likely
already been growing for a number of years. We therefore further on use the term “earlier”
rather than “early” stage.
To date, there exists no reliable, non-invasive screening test, either molecular or
imaging-based, that will allow accurate PDAC detection at an earlier stage in asymptomatic
patients. The conventional methods such as computerized tomography, magnetic resonance
imaging or endoscopic ultrasonography are expensive and have low sensitivity (SN) and
specificity (SP) for detection of small premalignant lesions [16]. Furthermore, the deep
anatomic location of the pancreas makes detection of small-localized tumors unlikely
during a routine abdominal examination [17].
In contrast, testing for biomarkers in body fluids such as serum, plasma, urine or
saliva is minimally invasive, relatively inexpensive and could allow for earlier PDAC
diagnosis [18]. The current gold-standard serum biomarker for PDAC is carbohydrate
antigen 19-9 (CA19-9), also known as sialylated Lewis (a) antigen. It is a product of
exocrine epithelial cells and various mucins secreted by PDAC cells that are normally
found on the surface of erythrocytes [19]. The test was approved by the U.S. Food and
Drug Administration (FDA) in 2002 [20]. However, it is recommended to be used only
for disease monitoring and prognosis, since the performance of CA19-9 as a diagnostic
biomarker is limited by poor SN, false-negative results in the individuals with Lewis
negative phenotype and increased false positivity in several benign and malignant biliary
disorders [21]. Furthermore, CA19-9 is not recommended as a screening marker due to its
low positive predictive value (0.5–0.9%) [22–24].
The accuracy of any tumor biomarkers assay, including CA19-9, is linked to the
concept of threshold, or cut-off [25]. The CA19-9 cut-off values differ significantly between
studies due to the lack of an international standard for CA19-9 and the difference in the
assay design and instrument utilized [26]. When the two most frequently used assays
for measuring CA19-9, Abbott Architect CA 19-9XR and Roche Elecsys CA19-9, were
compared, despite being based on the same monoclonal antibody 1116-NS-19-9 [27], the
Abbott assay measured significantly lower CA19-9 values than the Roche one in healthy
and benign cases [28]. While the upper reference limit of 37 U/mL, reaching mean SN and
SP of 81% and 90%, respectively, as first reported by Steinberg [29], is still able to sufficiently
differentiate between controls and PDAC, the CA19-9 values obtained by different methods
should not be used interchangeably, the method utilized should be clearly stated and the
patients should be monitored using the same assay [28,30]. Thus, despite its role as the
principle serological test for PDAC, the standardization of the laboratory testing and correct
interpretation of high serum CA19-9 levels with the adequately established cut off has not
yet been achieved [31]. The search for a new non-invasive PDAC biomarker with superior
SN and SP to CA19-9, which will be easily identifiable and robustly measured in a fully
standardized fashion in biofluids, is therefore being actively pursued.
Recent advances in molecular techniques have empowered the discovery of novel
biomarkers for earlier detection of PDAC, resulting in a significant and constantly growing
body of literature. Despite the discovery of thousands of biomarkers, relatively few
have been adequately tested and validated, making the assessment of their potential
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challenging [32]. This sparked an EDRN (The Early Detection Research Network) workshop
at National Cancer Institute (NCI) in 2016, where a selection of the most promising studies
was reported [33]. A comprehensive update and critically appraised resource of information
on potentially useful novel biomarkers for PDAC is, however, needed.
In the present study, we reviewed over 4000 articles and further assessed 49 published
studies from the last decade describing biomarkers in serum, plasma, urine and saliva for
earlier PDAC detection, in conjunction with serum CA 19-9, when available. We utilized
the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) to assess the
quality of the selected studies and highlighted their potential clinical utility and limitations
for earlier PDAC detection.
2. Methods
Two of the authors (G.B. and V.S.) independently conducted a systematic search of
MEDLINE, Web of Science and Embase and assessed all the articles published between
January 2010 and August 2020. A robust reproducible search strategy was created which
utilized the MESH terms “Pancreas OR Pancreatic” AND “Ductal Adenocarcinoma OR
PDAC OR Cancer OR Malignancy OR Adenocarcinoma OR Tumour OR Tumor” AND
“Liquid Biopsy OR Biomarkers OR Screening OR Stool OR Markers OR Marker OR Urine
OR Saliva OR Blood OR Non-invasive OR Non Invasive OR Fluid Biopsy OR Fluid Phase
Biopsy OR Detection OR Diagnosis OR Diagnose OR Screen” to search for the potential
biomarkers specific for this disease. The filters were adjusted to show the results for
studies in the English language only. The article type was set to only include clinical
and observational studies in Medline. In Medline and Embase, titles and abstracts were
searched. In Web of Science, only titles were searched. PRISMA guidelines were used to
assist in the structuring of this systematic review [34]. The inclusion and exclusion criteria
for selecting the studies are listed in Table 1.
Table 1. Inclusion and Exclusion Criteria for study selection.
Inclusion Criteria
1. Pancreatic Ductal Adenocarcinoma
2. Non-invasive method of obtaining a liquid biopsy e.g., plasma, serum, urine, saliva, stool
3. Original data with reported AUC, SN and SP of a proposed biomarker
4. Human studies
5. Manuscripts from January 2010 until August 2020
Exclusion Criteria
1. No specification of what type of pancreatic cancer it was
2. Invasive procedures to obtain the biomarker e.g., tissue biopsy
3. No recorded data either of SN, SP and/or AUC for the tested biomarker
4. Biomarker used for a purpose other than detection e.g., prognostic biomarkers
5. Abstracts, Conference reports/writings, NHS reports, Review Articles
Abbreviations: AUC—Area Under the ROC (Receiver Operating Characteristic) Curve, SN—Sensitivity, SP—
Specificity, NHS—National Health Service in UK.
Assessment of the methodological quality of reviewed articles was performed ac-
cording to QUADAS-2, a validated quality assessment tool commonly used to assess the
methodology of investigated studies, and as a measure to improve diagnostic accuracy [35].
With QUADAS-2, we were able to appraise three key domains, namely Patient Selection,
Index Test and Reference Standard, for both risk of bias and applicability. For the Patients
selection, we assessed if the sample groups were well described and if patient spectrum
was representative of the disease. We also assessed if the selection of the controls was
appropriate, i.e., if, in addition to healthy controls, samples collected from patients with
benign pancreatic diseases at risk for progressing to PDAC were also included. Within
the Applicability concerns, we assessed if the data for PDAC stages I/II were reported,
as we were aiming to review biomarkers for earlier detection of PDAC. For the Index test
(biomarker assay), we appraised how well the assay was described and executed and the
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results interpreted (SN/SP/AUC with 95% confidence intervals (CIs)) and if the data were
split into training and validation sets. To increase the validity of the results, QUADAS-2
also recommends that researchers do not know which study group each patient belongs
to (“blinding”) in order to reduce the effects of any foreknowledge in the interpretation
of the biomarker assay results [36]. QUADAS-2 includes the need to specify a threshold
value for the Index test prior to obtaining the results; however, this is not suitable for newly
discovered biomarkers, where one of the aims is to determine the appropriate cut-offs
with regards to the SN, SP and AUC. For the Reference Standard, we assessed if the study
specifies that PDAC diagnosis was confirmed by histology and if the staging was patho-
logical or clinical. However, as biomarker discovery studies are typically performed on
retrospectively collected samples with an already established diagnosis, we additionally
included a comparison of the new biomarker with CA19-9. Flow and Timing were excluded
from our QUADAS-2 scoring, as it was difficult to assess this parameter, i.e., in the majority
of the studies, it was unclear in what time frame were the diagnostic biopsy or imaging
performed in respect to the sample collection and the biomarker testing.
3. Results and Discussion
A PRISMA flow diagram demonstrating the search strategy and study selection
criteria that were applied is shown in Figure 1.
Figure 1. PRISMA Flow diagram of the search strategy and study selection.
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The overall quality of the 49 selected and reviewed studies is illustrated in Figure 2.
Figure 2. Graphical representation of the overall quality of the selected studies.
In Figure 2 it is evident that the majority of the studies (70%) had a low risk of bias
in the Reference Standard domain, as the information on histological confirmation that
samples originated from PDAC was specified. The unclear bias in this domain seen in
approximately 30% of the studies was due to the absence of comparison of biomarkers
with CA19-9. High risk of bias in the Index test (biomarker assay) was seen in 36% of
studies and was associated with missing information on if the samples were analyzed in
the blinded fashion. The lack of clarity, which was seen in the following 36% of the studies,
was due to absence of robust statistical analysis of the data, i.e., splitting of the data into the
training and the validation sets. Regarding patient selection criteria, around 20% of studies
did not compare PDAC results to appropriate benign controls, leading to a high risk of
bias. Around 20% of studies raised concerns about the applicability of the biomarkers for
earlier PDAC detection, as they were not assessed in resectable stage I–II PDAC.
A graphical summary of the QUADAS-2 results with the descriptive score for each of
the selected studies is presented in a tabular form in supplementary Appendix A, Table A1.
Table 2 summarizes the key findings from all 49 studies included in this review.
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Table 2. Key findings from included studies.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC




























Brand et al., 2011 [17] Serum
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109 PDAC,
40 HC, 30 CP

















CA19-9 + Cathepsin D + MMP-7
129 PDAC,
74 HC, 72 CP













0.91 (p = 0.002)
Capello et al.,
2013 [40] Serum
EZR-autoantibody 69 PDAC, 46 CP, 60 HC,
12 Aim, 50 Non-PDAC
PDAC vs. HC + CP +
Aim 93.2 75.5 0.90
PDAC vs. non-PDAC
cancer 94.9 96.4 0.99
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Nolen et al., 2014 [47] Serum
CA19-9
CA19-9 + CEA
CA19-9 + CEA + Cyfra 21-1




























Ren et al., 2014 [48] Serum IL-11p 44 PDAC, 30 HC PDAC vs. HC 97.7 70.0 0.901 (p < 0.001)
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Zhang et al.,
2014 [51] Serum
CA19-9 + Albumin + CRP + IL-8
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CA19-9 + Albumin + CRP + IL-8
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Melo et al., 2015 [54] Serum
GPC1 + crExos
CA19-9
190 PDAC, 100 HC,
26 BPD
DS:









56 PDAC, 20 HC,
6 BPD
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143 PDAC (stage I-IV),
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49 PDAC (stage I-IV), 28
HC VS: PDAC vs. HC 75.5 100 0.92 (0.84–1.00)
LYVE1 + REG1A + TFF1 +
(Creatinine +Age)
56 PDAC (stage I-II), 61
HC 80.0 76.9 0.93 (0.84–1.00)
Plasma CA19-9
Panel (LYVE1 + REG1A + TFF1)
Panel + Plasma CA19-9




















non-adenocarcinoma 78.0 96.4 0.87 (0.80–0.94)
Guo et al., 2016 [57] Serum
DTNBP1
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Henriksen et al.,
2016 [58] Plasma
(Model13): age >65+ BMP3+ RASSF1A+ BNC1+
MESTv2+ TFPI2+ APC+ SFRP1 +
SFRP2
95 PDAC, 97 CP,
27 “screened negative”
PDAC vs. screened
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et al., 2017 [61] Plasma
CA19-9 55 PDAC (stage IA/ IB-IIA),61HC Stage IA/ IB-IIA vs. HC 71.0 61.0 0.74 (0.64–0.84)
TNC + TFP1 + CA19-9 55 PDAC (stage IA/ IB-IIA),62 CP Stage IA/ IB-IIA vs. CP 73.0 82.0 0.79 (0.70–0.87)
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Capello et al., 2017 [63] Serum/
Plasma
CA19-9
TIMP1 + LRG1 + CA19-9
TIMP1 + LRG1 + CA19-9 (“OR”
Rule)
CA19-9
39 early stage PDAC,
82 HC















TIMP1 + LRG1 + CA19-9
73 early stage PDAC,
60 HC

























0.94 (p < 0.001)
1.00 (p < 0.001)
1.00 (p < 0.001)
0.92 (p < 0.001)
Kaur et al., 2017 [65] Serum
MUC5AC
CA19-9











































58 (stage I-II, phase 2a),
80 HC

























































0.92 (p < 0.001)
1.00 (p < 0.001)
0.95 (p < 0.001)
1.00 (p < 0.001)
0.98 (p < 0.001)
0.99 (p < 0.001)
0.97 (p < 0.001)
0.67 (p = 0.20)
0.99 (p < 0.001)
0.89 (p = 0.003)
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Park et al.,
2017 [68] Serum
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
80 PDAC (50 stage I-II) (29 CA19-9
negative PDAC), 68 HC, 21 BPD, 52
Thyroid Ca, 52 Breast Ca, 45
Colorectal Ca)
PDAC vs. HC + BPC (n = 89)
PDAC stage I-II vs. HC + BPC
(n = 89)
PDAC vs. Other Cancers
(n = 149)
PDAC vs. BPD
CA19-9 negative PDAC (n = 29)





















0.93 (p < 0.01)
0.83
0.91 (p < 0.01)
0.79










82 PDAC, 191 HC
60 PDAC (stage I-II),
191 HC
PDAC vs. HC








et al., 2018 [70] Urine Volatile organic compounds
4 PDAC stage I, 5 stage IIA, 35 stage
IIB, 24 stage III, 12 stage IV,
81 HC
TS: PDAC vs. HC
VS:
PDAC vs. HC
PDAC stage I -II vs. HC
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30 PDAC (early stage),
68 PDAC (late stage),
32 BPC,
37 HC,
27 PDAC (CA19-9 negative)
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77 PDAC (late stage),
43 BPC;
37 HC,
29 PDAC (CA19-9 negative)
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
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Guo et al., 2018 [72] Serum SNHG15 171 PDAC, 59 HC PDAC vs. HC 68.3 89.6 0.73 (p < 0.01)
Lewis et al., 2018 [73] Whole blood,plasma, serum GPC1 + CD63
20 PDAC
6 BPD PDAC vs. BPD 81 70 0.79 (0.99–1.00)
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Table 2. Cont.
Reference SpecimenType Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC






























THBS2 + CA19-9 + cfDNA
VS:
















Eissa et al., 2019 [78] Plasma
ADAMTS1 39 PDAC,95 HC PDAC vs. HC 87.2 95.8 0.91 (0.77–0.90)
BNC1 64.1 93.7 0.79 (0.63–0.78)
ADAMTS1 and/or BNC1 97.4 91.6 0.95 (0.71–0.86)
Fahrmann et al.,
2019 [79] Plasma





PDAC vs. HC 69.0 99.0 0.90 (0.818–0.989)


























Yu et al., 2019 [80] Plasma
d-signature: EV long RNA (FGA,
KRT19, HIST1H2BK, ITIH2,
MARCH2, CLDN1, MAL2 and
TIMP1)
284 PDAC, 100 CP, 117 HC
PDAC vs. CP vs. HC
d-signature with
CA19-9
93.68 91.57 0.936 (0.889–0.983)
Takahashi et al.,
2019 [81] Serum Circulating EV-encapsulated HULC 20 PDAC, 22 IPMN, 21 HC PDAC vs. IPMN vs. HC 80 92.1 0.92
Wei et al., 2019 [82] Plasma Vimetin-positive CTCs 100 PDAC, 16 IPMN, 30 HC PDAC vs. IPMN vs. HC 65 100 0.968
Yang et al., 2020 [83] Plasma
EV miRNAs and mRNAs, cfDNA,
ccfDNA KRAS G12D/V/R
mutations and CA19-9
30 CP + BPC, 49 PDAC, 57
HC
PDAC vs. non-PDAC
vs. HC 88 95 0.95 (p = 0.103)
Abbreviations: Aim: autoimmune diseases; BBO: benign biliary obstruction; BBP: benign biliary pathology; BCT: benign cystic tumor; BPD: benign pancreatic disease; BPT: benign pancreatic tumor; CC:
cholangiocarcinoma; ccfDNA: circulating cell-free DNA; cf: circulating free; CP: chronic pancreatitis; CTC: circulating tumor cell; DC: discovery cohort; EV: extracellular vesicles; GC: gastric cancer; HC: healthy
control; HCC: hepatocellular carcinoma; HULC: highly upregulated in liver cancer; IPMN: intraductal papillary mucinous neoplasm; PC: prospective cohort; PDAC: pancreatic ductal adenocarcinoma; TS:
training set; VS: validation set. Note: 1 Depending on the concentration of cfDNA.
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The studies summarized in Table 2 were all aimed at earlier PDAC detection; however,
around 20% of them did not analyze their biomarkers in resectable stage I–II samples.
While the paucity of earliest stage I samples is a recognized problem in the PDAC field,
this was surprising, considering the critical importance of diagnostic stage shift. Selection
of the relevant control population is also of the essence, as PDAC is an uncommon cancer,
which dictates the need to assess the putative biomarkers in high-risk groups [1,84,85], a
criterion which was not satisfied in 20% of the studies. It also requires the high accuracy of
any potential future biomarker assay with at least 88% SN and 85% SP if the test is to be
cost-effective [86].
A third of the reviewed studies did not include a comparison of their biomarkers to
CA19-9, which was unexpected considering that CA19-9 is the most commonly measured
biomarker in PDAC patients. Very few biomarkers were conclusively superior to CA19-9
and in the majority of studies where their combination was tested, the accuracy of PDAC
detection was superior to either biomarker alone. For example, Dong et al. [71] described
the panel of serum biomarkers comprising CA19-9, POSTN and CA242, which was superior
to CA19-9 alone in differentiating between PDAC and both healthy controls (AUC of 0.98,
92.1% SN and 97.3% SP) and benign pancreatic conditions (AUC of 0.93, 80% SN and 97.7%
SP), albeit with somewhat lower AUC of 0.90 and a decrease in SP to 88% in resectable
PDAC. In the study of Berger et al. [77], CA19-9 combined with THBS2 and cfDNA in PDAC
vs. non-PDAC patients showed an increase in AUC from 0.70 to 0.78, with an increased
SN and SP of 80% and 96%, respectively. A study by Fahrmann et al. [79] combined a
five-metabolite panel (acetylspermidine, diacetylspermine, an indole-derivative and two
lysophosphatidylcholines) with a previously validated protein panel comprising CA19-9,
TIMP1 and LRG1, achieving AUC of 0.924 (95% CI 0.864–0.983). Recently, another panel
(FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) obtained by
plasma extracellular vesicle long RNA profiling (d-signature), successfully differentiated
PDAC from CP and healthy controls with AUC of 0.936, and both SN and SP > 90%;
furthermore, when combined with CA19-9, the signature showed improved AUC of 0.964
(95% CI: 0.943–0.984) [80]. Traeger et al., reported that miRNA-205 combined with CA19-9
resulted in higher SN and SP in comparison of PDAC vs. benign specimens (86.7% SN and
93.3% SP) than either of the biomarkers alone [75].
The absolute SN and SP values for PDAC detection using glypican-1 (GPC1) in cir-
culating exosomes when PDAC samples were compared to healthy and benign samples
was reported by Melo et al. [54]. However, several subsequent studies failed to support
these findings [62,73,87,88], while Zhou et al. [76] demonstrated that combining GPC1
and CA19-9 showed 92.31% SN at 65.83% SP for distinguishing healthy, chronic pancre-
atitis and benign pancreatic tumors from PDAC. Regardless of the underlying reasons,
these conflicting results highlight the critical importance of independent validation of any
proposed biomarkers.
The above study [54] and the more recent studies indicate the “expansion” of the
biomarker field, moving from the “traditional” DNA, RNA and protein biomarkers to
novel, versatile analytes and their combinations, such as non-coding RNAs, epigenetic
markers, lipids and metabolites, as well as circulating tumor cells and extracellular vesicles
(EV) [88]. For example, Yang et al. [83] performed a multi-parametric analysis of blood
tumor-associated EV miRNA and mRNA, circulating cell-free DNA concentration and
KRAS G12D/V/R mutations with CA19-9, and demonstrated their higher accuracy for
PDAC staging (84%) than imaging alone (accuracy = 64%; P < 0.05). Furthermore, recent
advances in computer science, machine learning and artificial intelligence (AI) have given
rise to the emerging field of bioinformatics and computational biology which allow analyses
of large collections of biological data [89]. While AI was mostly utilized for the prediction
of risk/diagnosis based on health records or abdominal imaging [1,90,91], it also shows a
great potential for in silico discovery of putative novel biomarkers. For example, Khatri
and Bhasin [92] used transcriptomics-based meta-analysis of tissue and blood samples
combined with machine learning to identify a nine-gene panel (IFI27, ITGB5, CTSD, EFNA4,
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GGH, PLBD1, HTATIP2, IL1R2 and CTSA) that differentiated PDAC and healthy controls
with 92% SN and 90% SP. Moreover, this panel also discriminated PDAC from chronic
pancreatitis and early precursor lesions in non-malignant tissue and peripheral blood.
Chung et al. [93] used probe electrospray ionization mass spectrometry (PESI-MS) and a
machine learning approach to analyze peripheral blood samples and achieved an accuracy
of 92.1% in healthy vs. PDAC (90.8% SN, 91.7% SP). The combination of PESI-MS profiles
with age and CA19-9 increased the accuracy for detection of stage I and II PDAC to 92.9%
(81.2% SN, 96.8% SP) [40]. This demonstrates that the access to richly annotated patients’
health records will enable the construction of novel PDAC prediction tools such as the
one developed by Muhammad et al. [90]. Combining such prediction tools with biofluid
biomarkers now opens up promising new avenues and likely a fruitful approach to identify
asymptomatic patients at increased risk of developing PDAC.
Very few studies explored the effectiveness of their proposed biomarkers in pre-
diagnostic samples from asymptomatic patients. Although such samples are not readily
available, these studies are essential for determining how early in the latency period
the biomarkers can be detected [40,47,94–101]. Nolen et al. [47] interrogated the large
prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial serum
samples to detect eight biomarkers: CEA-related cell adhesion molecule 1 (CEACAM1)
and prolactin (PRL) were detectable up to 35 months before PDAC diagnosis; CA19-9,
carcinoembryonic antigen (CEA), neuron-specific enolase (NSE) and beta-human chorionic
gonadotropin (b-HCG) up to 24 months; and CA125 and interleukin 8 (IL-8) up to 12
months prior PDAC diagnosis. In the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) serum samples, a decrease in circulating TSP-1 levels up to 24 months prior to
PDAC diagnosis was described by Jenkinson et al. [97], and O’Brien et al. demonstrated
that CA19-9 could be detected in such pre-diagnostic PDAC samples with 95% SP and 68%
SN up to 1 year and 53% SN up to 2 years prior to PDAC diagnosis [98]. A three-biomarker
panel comprising Erb-B2 receptor tyrosine kinase 2 (ERBB2), estrogen receptor 1 (ESR1)
and tenascin C (TNC) was analyzed in 87 pre-diagnostic plasma samples from Women’s
Health Initiative (WHI) collected up to 4 years before diagnosis and achieved AUC of 0.71
when combined with CA19-9 [100]. Recently, the analysis of 1196 proteins in longitudinal
plasma samples from the Institute for Systems Biology’s 100K Wellness project identified
several markers, including three that were observed in PDAC: CEA cell adhesion molecule
5 (CEACAM5) was expressed at high levels 26.5 months pre-diagnosis, while calcitonin
related polypeptide alpha (CALCA) and delta1 like homolog (DLK1) were predating PDAC
diagnosis for around 17 months [101]. More exciting projects such as this are needed and
should be actively encouraged.
While performing this review, we encountered a number of hurdles, particularly
noticeable in the way the studies were reported. Easier reviewing of published resources
would be facilitated, and the extraction of the relevant information simplified, if a consen-
sus set of standards for the reporting of biomarker studies were utilized. In addition to
QUADAS-2, several of such recommendations and guidelines exist: BRISQ (Biospecimen
Reporting for Improved Study Quality) [102] provides recommendations for reporting
details about the interrogated biospecimens; the Standards for Reporting of Diagnostic
Accuracy Studies (STARD) [103] was developed to improve the completeness and trans-
parency of the reports; and Reporting Recommendations for Tumour Marker Prognostic
Studies (REMARK) [104] and Consolidated Standards of Reporting Trials (CONSORT
Statement) [105] are used to improve the overall quality of tumor markers in the prognostic
studies and randomized trials [104,105] . The latter is the final step in establishing the
clinical utility of the biomarker, i.e., increased survival due to earlier diagnosis achieved
by biomarker testing. Interestingly, only studies published in high-impact factors journals
followed any of these recommendations [49,54,66,74,80].
In addition to the standardized way of reporting, a standardized pathway for early
detection and diagnosis is also needed. Such pathway has recently been summarized
in the updated Cancer Research UK (CRUK) roadmap, which aims to consolidate the
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current diverse and fragmented research activities, in line with the future vision to detect
75% of cancers at stage I-II by 2028 [106]. A roadmap also illustrates a long way from
biomarker discovery to its implementation, with a number of hurdles encountered at
every step in biomarker pipeline, from initial biomarker discovery, its quantification,
verification and assay optimization to finally biomarker validation and commercialization,
as comprehensively discussed previously [107–109]. While biomarker discovery is usually
well funded and results straightforward to report, validation, which is a necessary step
prior to commercialization, is time-consuming and expensive process, with scarce funding
available. The transition from discovery to the clinical utility of any biomarker is therefore
a cumbersome process, akin to the implementation of novel therapeutic [110].
It is not surprising thus that, despite a large number of candidate biomarkers, very
few are close to clinical implementation. Based on the accuracy of 95% of serum biomarker
signature published by Mellby et al. [74] and using their proprietary antibody platform,
Immunovia is now developing the commercial assay IMMRay™ PanCan-d, which is
currently being further validated in the prospective studies [111]. Our urinary biomarker
panel comprising REG1B, LYVE1, TFF1 and the affiliated PancRISK score [112,113] are now
being validated in a prospective study UroPanc [114] . A multi-analyte blood test that
simultaneously evaluates the levels of eight cancer proteins and the presence of cancer
gene mutations from circulating DNA, CancerSEEK®, screens for eight common cancers,
including PDAC [115], and has already been commercialized. GRAIL is advocating its own
Galleri test, which is based on cfDNA methylation signal and can detect over 50 different
cancers [116]. Both platforms, however, suffer from lower SN in detecting stage I cancers,
and there is a legitimate concern that the tests might be less specific in real-world conditions,
where comorbidities may increase the risk of a false-positive result [117].
4. Conclusions
In summary, our systematic review demonstrates the current progress in the biomarker
field and highlights several promising non-invasive PDAC biomarkers. Most of these,
however, still require further validation prior to being deemed appropriate for translation
into the clinical setting. All future studies should aim to improve methodological quality
and the way of reporting. Novel biomarkers that have shown promising results should be
further investigated on a larger number of specimens, as well as in a pre-diagnostic and
prospective setting, to further demonstrate their real clinical utility in earlier detection of
pancreatic adenocarcinoma.
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Appendix A
Table A1. Graphical summary of the QUADAS-2 scores for each of the 49 studies.
Nr. Study













1 Gold et al., 2010 [37] , ? ? , , , Low
2 Joergensen et al., 2010 [38] , ? , , , , Low
3 Marten et al., 2010 [39] / ? , / ? , High
4 Brand et al., 2011 [17] , , ? / , , Low
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5 Park et al., 2012 [21] , ? , , , , Low
6 Capello et al., 2013 [40] , , , / , , Low
7 Gold et al., 2013 [41] , ? , , , , Low
8 Kobayashi et al., 2013 [42] , / , / , , Low
9 Li et al., 2013 [43] , , , , , , Low
10 Zhao et al., 2013 [44] / / ? , , , High
11 Chung et al., 2014 [45] , , , , , , Low
12 Lee et al., 2014 [46] , , , / , , Low
13 Nolen et al., 2014 [47] , , , / , , Low
14 Ren et al., 2014 [48] , , , , , , Low
15 Schultz et al., 2014 [49] , ? , , , , Low
16 Yang et al., 2014 [50] , / ? / ? , High
17 Zhang et al., 2014 [51] , ? , , , , Low
18 Debernardi et al., 2015 [52] / ? ? , , , High
19 Han et al., 2015 [53] , / , , , , Low
20 Melo et al., 2015 [54] , ? , , , , Low
21 Radon et al., 2015 [55] , ? , , , , Low
22 Ankeny et al., 2016 [56] , / ? , ? , High
23 Guo et al., 2016 [57] , , , / , , Low
24 Henriksen et al., 2016 [58] , / ? , , , Low
25 Sogawa et al., 2016 [59] , / , , , , Low
26 Yoneyama et al., 2016 [60] , ? , / , , Low
27 Balasenthil et al., 2017 [61] , , , , , , Low
28 Yang et al., 2017 [62] , ? , , ? , Low
29 Capello et al., 2017 [63] , ? , , , , Low
30 Hussein et al., 2017 [64] / / , / , , High
31 Kaur et al., 2017 [65] , , , , , , Low
32 Kim et al., 2017 [66] , , , , , , Low
33 Lai et al., 2017 [67] / / , / , , High
34 Park et al., 2017 [68] , / , , , , Low
35 Schott et al., 2017 [69] / / ? , , , High
36 Arasaradnam et al., 2018 [70] / ? ? , , , High
37 Dong et al., 2018 [71] , ? , , , , Low
38 Guo et al., 2018 [72] / / ? , , , High
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39 Mellby et al., 2018 [74] , ? , , , , Low
40 Traeger et al., 2018 [75] , / , , , , Low
41 Zhou et al., 2018 [76] , / , / ? , High
42 Berger et al., 2019 [77] , , , , , , Low
43 Eissa et al., 2019 [78] , / ? , , , Low
44 Fahrmann et al., 2019 [79] , , , , , , Low
45 Lewis et al., 2019 [73] , ? ? / ? , High
46 Yu et al., 2019 [80] , / , , , , Low
47 Takahashi et al., 2019 [81] , / ? , ? , High
48 Wei et al., 2019 [82] , / , , ? , Low
49 Yang et al., 2020 [83] , , , , ? , Low
, Low Risk; / High Risk; ? Unclear Risk.
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